Tue, Dec 23, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

Investors should prepare portfolios for eventual rise in interest rates - Credit Suisse

Thursday, May 10, 2012

Bailey McCann, Opalesque New York: Investors may want to start preparing their portfolios for the impact of a rise in interest rates according to a new report from Credit Suisse Asset Management. Although still muted, the strengthening economy has re-ignited inflation concerns and the report authors caution that investors need to start thinking about repositioning their portfolios now to avoid future potential pitfalls.

In this environment, investors can benefit from an allocation beyond core fixed income, especially at the non-investment grade end of the spectrum, according to John Popp, Global Head and Chief Investment Officer of the Credit Investments Group and author of the paper.

"The Fed’s decision as to when to raise rates next is crucial. A move to higher rates may signal a sustained period of US economic improvement, but a sharp increase could derail the recovery," writes Popp. He suggests trading duration risk for credit risk may be prudent for investors.

The report notes that high-yield bonds offer compelling defensive value based on their present average duration and recent call protection dynamics.

"We believe high-yield bonds and senior loans are attractive alternatives for fixed income investors who are seeking to preserve value and drive incremental yield," Popp writes. Adding investment grade debt may also add yield while mitigating risk according to data presented in the paper.

The report, Beyond the Core: Preparing Portfolios fo......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for